Skip to content

Drug Testing and Analysis

ISSN 1942-7603

59 papers in the library · 1,924 citations · publishing 2010-2026

Papers

5‐(2‐Aminopropyl)indole (5‐IT): a psychoactive substance used for recreational purposes is an inhibitor of human monoamine oxidase (MAO)

Drug Testing and Analysis September 20, 2013 Tomás Herraiz, Simon D. Brandt 25 citations

5-(2-Aminopropyl)indole (5-IT), a psychoactive compound linked to fatal and non-fatal intoxications in Europe, was tested for its effect on human monoamine oxidase (MAO) enzymes. Using kynuramine as a substrate, 5-IT selectively, competitively, and reversibly inhibited MAO-A with an IC50 of 1.6 μM and a Ki of 0.25 μM, while showing no inhibition of MAO-B up to 500 μM. Compared to established inhibitors, 5-IT was less potent than clorgyline (IC50 16 nM) and harmaline (20 nM) but more potent than toloxatone (6.7 μM) and moclobemide (>500 μM). This MAO-A inhibition suggests 5-IT may contribute to serotonergic toxicity, though further research is needed.

Pharmacokinetics and subjective effects of 1P‐LSD in humans after oral and intravenous administration

Drug Testing and Analysis May 16, 2020 Christina Grumann, Kerstin Henkel, Simon D. Brandt et al. 23 citations

1P-LSD, a non-controlled alternative to LSD, acts as a prodrug that converts almost entirely into LSD in the human body. In two volunteers, oral and intravenous doses of 100 μg 1P-LSD were administered. After oral intake, only LSD was detected in serum and urine, with a terminal elimination half-life of about 6.4 hours. Intravenous 1P-LSD was detectable for only a few hours, while LSD persisted much longer. The bioavailability of LSD from oral 1P-LSD was nearly 100%. Subjective drug effects and altered states of consciousness scores were comparable to those from LSD, supporting the prodrug hypothesis. Oral administration produced higher 5D-ASC scores than intravenous.

Synthesis, characterization and monoamine transporter activity of the new psychoactive substance mexedrone and its N‐methoxy positional isomer, N‐methoxymephedrone

Drug Testing and Analysis August 15, 2016 Gavin McLaughlin, Noreen Morris, Pierce V. Kavanagh et al. 23 citations

Mexedrone, a derivative of mephedrone that appeared in 2015, was synthesized and analytically characterized. It was a weak non-selective uptake blocker at dopamine, norepinephrine, and serotonin transporters with IC50 values in the low micromolar range, and lacked releasing activity at dopamine and norepinephrine transporters but showed weak releasing activity at serotonin transporters (EC50 = 2.5 μM). Its isomer, N-methoxymephedrone, acted as a weak uptake blocker and a fully efficacious substrate-type releasing agent across all three transporters with EC50 values in the low micromolar range. A synthesis by-product, α-chloromethylmephedrone, was inactive in all assays.

Identification and characterization of N‐tert‐butoxycarbonyl‐MDMA: a new MDMA precursor

Drug Testing and Analysis August 30, 2016 Michael Collins, Christopher Donnelly, Shane Cameron et al. 21 citations

A red liquid seized by Australian authorities as a suspected MDMA precursor was identified as N-tert.-butoxycarbonyl-MDMA (t-BOC-MDMA), a derivative that can be converted to MDMA under acidic conditions. In simulated gastric juice, most t-BOC-MDMA converted to MDMA within 305 minutes, suggesting it could act as a pro-drug in the body. Similar t-BOC derivatives of methamphetamine, pseudoephedrine, and mephedrone were also prepared. The appearance of such derivatives on the drug market warrants monitoring.

Preparation and analytical characterization of 1‐(1‐phenylcyclohexyl)piperidine (PCP) and 1‐(1‐phenylcyclohexyl)pyrrolidine (PCPy) analogues

Drug Testing and Analysis April 2, 2013 Jason Wallach, Giorgia de Paoli, Adeboye Adejare et al. 21 citations

Six new psychoactive substances related to PCP and ketamine were synthesized and analyzed: three substituted 1-(1-phenylcyclohexyl)piperidines (3-MeO-, 4-MeO-, and 3-Me-PCP) and three substituted 1-(1-phenylcyclohexyl)pyrrolidine analogues (3-MeO-, 4-MeO-, and 3-Me-PCPy). Mass spectrometry, chromatography, infrared, and NMR spectroscopy characterized all six compounds and their intermediates. Solvent and protonation effects on NMR spectra were examined. Isomeric 3-MeO- and 4-MeO-PCP and PCPy analogues could be distinguished by mass spectrometry. Gas chromatography caused notable degradation of 4-MeO-substituted analytes, especially hydrochloride salts, producing a 1-phenylcyclohex-1-ene nucleus; this degradation was less pronounced with 3-MeO isomers, likely due to para-methoxy group resonance facilitating amine elimination.

Magic truffles or Philosopher's stones: a legal way to sell psilocybin?

Drug Testing and Analysis August 9, 2012 Manuela Pellegrini, Maria Concetta Rotolo, Emilia Marchei et al. 21 citations

A liquid chromatography–tandem mass spectrometry method was developed to rapidly measure psilocybin and psilocin in Psilocybe sclerotia, known as magic truffles. After a simple methanol extraction, the alkaloids were separated on a reversed-phase column and detected using electrospray ionization tandem mass spectrometry. The method was linear over the calibration range with correlation coefficients above 0.99, detection limits of 0.3 µg per 100 mg, and quantification limits of 1 µg per 100 mg. Only psilocybin was found in the examined sclerotia, with concentrations ranging from 59.3 to 167.8 µg per 100 mg of fresh material.

Return of the lysergamides. Part VII: Analytical and behavioural characterization of 1‐valeroyl‐d‐lysergic acid diethylamide (1V‐LSD)

Drug Testing and Analysis November 27, 2021 Simon D. Brandt, Pierce V. Kavanagh, Folker Westphal et al. 19 citations

A new LSD derivative called 1-valeroyl-LSD (1V-LSD, or "Valerie") has appeared on the online market. It is a higher homolog of earlier derivatives like ALD-52, 1P-LSD, and 1B-LSD. The study analytically characterized 1V-LSD using mass spectrometry, chromatography, NMR, and Raman spectroscopy. In mice, 1V-LSD induced a head-twitch response, a behavioral proxy for human hallucinogenic effects, in a dose-dependent manner. Its median effective dose was 373 nmol/kg, about a third the potency of LSD (ED50 = 132.8 nmol/kg). 1V-LSD likely acts as a prodrug that is hydrolyzed to LSD, but further studies on its biotransformation and receptor pharmacology are needed.

A rapid and simple method for the determination of psychoactive alkaloids by CE‐UV: application to Peganum Harmala seed infusions

Drug Testing and Analysis July 5, 2016 Marcos Tascón, Fernando Benavente, Nora M. Vizioli et al. 18 citations

The β-carboline alkaloids of the harmala group (HAlks), found in plants like Peganum harmala (Syrian rue) and Banisteriopsis caapi, act as reversible monoamine oxidase type A inhibitors (MAOIs). Their levels in natural sources vary greatly, limiting clinical use and leading to recreational or ritual use, such as in Ayahuasca. This work presents a fast, simple, and robust method using capillary electrophoresis with UV detection to simultaneously quantify six common HAlks: harmine, harmaline, harmol, harmalol, harmane, and norharmane. The method was applied to analyze P. harmala seed infusion, detecting harmaline, harmine, and harmol. Validation across three instruments showed transferability and comparable performance.

Synthesis, characterization, and monoamine transporter activity of the new psychoactive substance 3′,4′‐methylenedioxy‐4‐methylaminorex (MDMAR)

Drug Testing and Analysis October 20, 2014 Gavin McLaughlin, Noreen Morris, Pierce V. Kavanagh et al. 18 citations

A newly emerged psychoactive substance, 3,4-methylenedioxy-4-methylaminorex (MDMAR), was synthesized and characterized. Analysis of vendor-sourced MDMAR found it to be predominantly the cis-isomer (90%), which could artificially convert to the trans-isomer under certain liquid chromatography conditions. Both MDMAR isomers, along with cis- and trans-4,4'-DMAR, were more potent than MDMA in releasing dopamine and norepinephrine in rat brain tissue. While cis-4,4'-DMAR, cis-MDMAR, and trans-MDMAR fully released serotonin, trans-4,4'-DMAR acted as a serotonin uptake blocker. The high potency of these analogues at monoamine transporters may indicate potential for serious side-effects at high doses.

Investigating the ability of the microbial model Cunninghamella elegans for the metabolism of synthetic tryptamines

Drug Testing and Analysis November 21, 2018 Katharina Elisabeth Grafinger, Andreas Wilke, Stefan König et al. 15 citations

A fungus, Cunninghamella elegans, can mimic human drug metabolism and was tested on four tryptamines: DMT, 4-HO-MET, 5-MeO-DALT, and 5-MeO-MiPT. After 72 hours of incubation, the fungus performed key biotransformation steps like hydroxylation, N-oxide formation, carboxylation, deamination, and demethylation. On average, 63% of phase I metabolites previously reported in the literature were also produced by C. elegans, along with some unique metabolites. The findings suggest C. elegans is a useful complementary model for studying the metabolism of natural and synthetic tryptamines, especially given the lack of pharmacological data for new psychoactive substances.

Analytical profile, in vitro metabolism and behavioral properties of the lysergamide 1P‐AL‐LAD

Drug Testing and Analysis May 7, 2022 Simon D. Brandt, Pierce V. Kavanagh, Folker Westphal et al. 14 citations

The lysergamide 1P-AL-LAD is characterized and tested in vitro and in mice. In pooled human liver microsomes, 1P-AL-LAD converts to AL-LAD as the most abundant metabolite, supporting the idea that it acts as a prodrug. Fourteen metabolites are detected, including hydroxylation and deacylation products. In mice, 1P-AL-LAD produces a dose-dependent increase in head twitch response, a behavioral proxy for human hallucinogenic effects, with an inverted U-shaped dose-response curve. Its median effective dose is 491 nmol/kg, almost three times less potent than AL-LAD (174.9 nmol/kg). The prodrug mechanism likely explains its activity despite N1-substitution disrupting 5-HT2A receptor activation.

Characterization of the synthesis of N,N‐dimethyltryptamine by reductive amination using gas chromatography ion trap mass spectrometry

Drug Testing and Analysis July 1, 2010 Simon D. Brandt, Sharon A. Moore, Sally Freeman et al. 14 citations

An impurity profile was established for a synthetic route to the hallucinogen N,N-dimethyltryptamine (DMT) using reductive amination of tryptamine with formaldehyde and reduction by sodium cyanoborohydride. Seven compounds were detected and quantified, including DMT and several byproducts. Replacing sodium cyanoborohydride with sodium borohydride almost exclusively produced tetrahydro-β-carboline instead of DMT. Detection limits ranged from 21.5 to 87.7 ng mL⁻¹, and quantification limits from 24.6 to 88.3 µg mL⁻¹, with linearity from 20.8 to 980 µg mL⁻¹. The method is useful for forensic and pharmaceutical analysis of DMT.

In vitro phase I metabolism of three phenethylamines 25D‐NBOMe, 25E‐NBOMe and 25N‐NBOMe using microsomal and microbial models

Drug Testing and Analysis July 3, 2018 Katharina Elisabeth Grafinger, Katja Stahl, Andreas Wilke et al. 13 citations

The metabolism of three hallucinogenic phenethylamines—25D-NBOMe, 25E-NBOMe, and 25N-NBOMe—was investigated using pooled human liver microsomes (pHLM) and the fungus Cunninghamella elegans. In pHLM, 36, 26, and 24 phase I metabolites were identified for 25D-NBOMe, 25E-NBOMe, and 25N-NBOMe, respectively; in C. elegans, 14, 11, and 9 metabolites were found. Major biotransformation steps included oxidative deamination, N-dealkylation, O-demethylation, hydroxylation, and oxidation of alcohols. Unique metabolites included N-oxide and hydroxylamine derivatives, reported for the first time for NBOMe compounds. C. elegans produced all main biotransformation steps observed in human microsomes, suggesting its potential as a model for studying new psychoactive substances.

Syntheses and analytical characterizations of N‐alkyl‐arylcyclohexylamines

Drug Testing and Analysis September 11, 2015 Jason Wallach, Tristan Colestock, Brian Cicali et al. 13 citations

Fifteen N-alkyl-arylcyclohexylamines, including compounds related to the dissociative substances 3-MeO-PCP, 3-MeO-PCE, and 3-MeO-PCPr, were synthesized and characterized. Analytical methods such as gas chromatography, mass spectrometry, and nuclear magnetic resonance spectroscopy were used. Positional isomers of methoxy-substituted arylcyclohexylamines were readily distinguishable under various analytical conditions. The work provides previously unreported analytical data to aid in identifying newly emerging research chemicals.

Discovery of a new caerulescent Psilocybe mushroom in Germany: Psilocybe germanica sp.nov.

Drug Testing and Analysis March 31, 2015 Jochen Gartz, Georg Wiedemann 13 citations

A new species of psychoactive mushroom, Psilocybe germanica, is described from Germany. It grows on wood chips and bark mulch in parks, fruits from September to December, and turns deep blue when bruised or aged. Chemical analysis showed it contains high levels of psilocybin and baeocystin but no psilocin, distinguishing it from other wood-loving Psilocybe species. Its stipe has a unique joint-like thickening near the cap, and its cap is not striate or translucent when wet. The authors suggest that, like Psilocybe cyanescens, this species may become widespread due to the increasing use of wood mulch in landscaping.

Separating the wheat from the chaff: Observations on the analysis of lysergamides LSD, MIPLA, and LAMPA

Drug Testing and Analysis May 22, 2021 Simon D. Brandt, Pierce V. Kavanagh, Folker Westphal et al. 12 citations

Lysergic acid diethylamide (LSD) is a potent psychoactive substance of clinical interest, and its analogs, including N-methyl-N-isopropyl isomer (MIPLA), have appeared on the street market. This report describes analytical methods to differentiate MIPLA from LSD and the N-methyl-N-propyl isomer (LAMPA) under routine conditions. Gas chromatography-solid phase infrared spectroscopy was particularly helpful. GC-electron ionization-tandem mass spectrometry of the m/z 72 iminium ion distinguished the three isomers on mass spectral grounds alone. Derivatization with BSTFA improved GC separation. LC-Q-MS and in-source collision-induced dissociation differentiated MIPLA and LAMPA based on distinct m/z 239 ion ratios. An alternative LC-MS/MS method improved separation but LSD co-eluted with iso-LSD; comparing ion ratios at m/z 324.2 > 223.2 and 324.2 > 208.2 facilitated differentiation. Two blotters contained 180 and 186 μg MIPLA per blotter.

Synthesis and characterization of high‐purity N,N‐dimethyltryptamine hemifumarate for human clinical trials

Drug Testing and Analysis July 1, 2020 Nicholas V. Cozzi, Paul F. Daley 12 citations

A slightly modified Speeter–Anthony synthesis produced DMT hemifumarate with over 99.9% purity, meeting regulatory standards for human intravenous administration. Aluminum hydride generated in situ from lithium aluminum hydride was used for the first time to reduce an intermediate to DMT, and a quench protocol yielded exceptionally pure free base DMT. The final salt was analyzed by multiple techniques including X-ray powder diffraction, NMR, GC–MS, and HPLC. No significant impurities or residual solvents were detected. The work supports planned clinical trials of DMT for major depressive disorder.

Synthesis and identification of deschloroketamine metabolites in rats' urine and a quantification method for deschloroketamine and metabolites in rats' serum and brain tissue using liquid chromatography tandem mass spectrometry

Drug Testing and Analysis October 31, 2019 Kateřina Hájková, Bronislav Jurásek, Jan Čejka et al. 12 citations

Deschloroketamine, a ketamine analog sold illicitly since 2015 and sometimes misrepresented as ketamine, has potential antidepressant properties. A metabolomics study used liquid chromatography–high-resolution mass spectrometry and a validated multiple reaction monitoring method to track its metabolites in urine, serum, and brain tissue. Key metabolites—trans-dihydrodeschloroketamine, cis- and trans-dihydronordeschloroketamine, and nordeschloroketamine—were synthesized and used as standards. In serum, nordeschloroketamine and deschloroketamine concentrations ranged from 0.5 to 860 ng/mL; in brain tissue, they ranged from 0.5 to 4700 ng/g. The quantification methods showed intra-day accuracy of 80–125% and precision averaging 3–7%.

Human hair tests to document drug environmental contamination: Application in a family law case involving N,N-dimethyltryptamine.

Drug Testing and Analysis October 23, 2020 P. Kintz, A. Ameline, J. Raul 10 citations

Hair tests can detect long-term drug use, but external contamination risks false positives. Advanced analytical equipment now allows precise quantification of drugs in hair at picogram per milligram levels. In a family law case, DMT was found in the hair of a partner of a repetitive DMT smoker at 4 to 13 pg/mg across six 1-cm segments, with concentrations increasing from proximal to distal ends. This pattern and low concentrations indicate environmental contamination rather than ingestion, as older hair had longer contact with the drug. Even after decontamination, environmental drugs can remain bound to hair, enabling documentation of exposure.

Synthesis and characterization of 5‐methoxy‐2‐methyl‐N,N‐dialkylated tryptamines

Drug Testing and Analysis January 1, 2012 Simon D. Brandt, Ruchanok Tearavarich, Nicola M. Dempster et al. 10 citations

Thirteen new tryptamine derivatives were synthesized and analyzed to provide reference data for forensic and clinical identification. Using NMR and mass spectrometry, the compounds were characterized and distinguished from each other and from related substances. Key mass spectral fragments were identified, including an iminium ion and indole-related ions at specific mass-to-charge ratios. The work extends earlier research on similar compounds and supplies analytical standards that can help professionals identify these substances before they cause adverse health effects.

Microwave‐accelerated preparation and analytical characterization of 5‐ethoxy‐N,N‐dialkyl‐[α,α,β,β‐H4]‐ and [α,α,β,β‐D4]‐tryptamines

Drug Testing and Analysis December 29, 2010 Ruchanok Tearavarich, Viwat Hahnvajanawong, Nicola M. Dempster et al. 10 citations

Twelve novel 5-ethoxy-N,N-dialkyl-tryptamines and their deuterated counterparts were synthesized using a microwave-accelerated reduction step that took 5 minutes in tetrahydrofuran at 150 °C. The resulting 24 tryptamines were characterized by nuclear magnetic resonance spectroscopy and gas chromatography ion trap mass spectrometry, revealing differential fragmentation of side-chain-related iminium ions. These compounds are intended as internal standards for bioanalytical and pharmacological assays, aiding identification of novel tryptamines from non-traditional sources, and are of immediate value in forensic, research, and public health contexts.

Syntheses and analytical characterizations of the research chemical 1‐[1‐(2‐fluorophenyl)‐2‐phenylethyl]pyrrolidine (fluorolintane) and five of its isomers

Drug Testing and Analysis April 30, 2019 Michael Dybek, Jason Wallach, Pierce V. Kavanagh et al. 9 citations

Six possible racemic isomers of the research chemical fluorolintane (2-F-DPPy) were synthesized and characterized. The isomers differ by the position of a fluorine substituent on the phenyl or benzyl ring of the 1,2-diarylethylamine structure. Using mass spectrometry, chromatography, nuclear magnetic resonance spectroscopy, and infrared spectroscopy, each isomer was distinguishable. A tandem mass spectrometry method analyzing the [M + H – HF]+ species produced distinct product ions for all six substances, aiding identification of positional isomers that pose challenges for stakeholders confronting new psychoactive substances.

Pharmacokinetic properties of 4‐fluoroamphetamine in serum and oral fluid after oral ingestion

Drug Testing and Analysis March 26, 2019 Stefan W. Toennes, David J. Schneider, Werner Pogoda et al. 9 citations

The pharmacokinetics of 4-fluoroamphetamine (4-FA) in humans resemble those of amphetamine, with peak serum concentrations occurring about 2 hours after ingestion and an elimination half-life of roughly 8-9 hours, though this varies widely (5.5-16.8 hours). After a 100 mg dose, median maximum serum concentration was 195 ng/mL (range 155-316 ng/mL). Concentrations in oral fluid were higher than in serum, especially during the first 3 hours, likely due to oral contamination. Serum concentrations observed in forensic cases matched those in the study, suggesting recreational doses are similar, but such doses may already cause prominent adverse effects and life-threatening consequences.

Synthesis, analytical characterization, and monoamine transporter activity of the new psychoactive substance 4‐methylphenmetrazine (4‐MPM), with differentiation from its ortho‐ and meta‐ positional isomers

Drug Testing and Analysis April 19, 2018 Gavin McLaughlin, Michael H. Baumann, Pierce V. Kavanagh et al. 8 citations

Two new psychoactive substances, 4-methylphenmetrazine (4-MPM) and 3-methylphenmetrazine (3-MPM), have appeared on the recreational drug market following the earlier emergence of 3-fluorophenmetrazine. Analytical characterization of vendor samples confirmed the presence of 4-MPM in two samples and 3-MPM in one sample. In vitro transporter assays using rat brain synaptosomes tested the isomers' ability to inhibit uptake or stimulate release of dopamine, norepinephrine, and serotonin. The findings suggest that 2-MPM and 3-MPM will exhibit stimulant properties similar to phenmetrazine, whereas 4-MPM may display entactogen properties more similar to MDMA. Combining test purchases, analytical characterization, targeted synthesis, and pharmacological evaluation provides an effective approach for generating data on emerging substances.

Drug laws and the 'derivative' problem

Drug Testing and Analysis August 15, 2013 Leslie A. King, István Ujváry, Simon D. Brandt 8 citations

The term 'derivative' has a precise but context-dependent meaning in chemistry, yet it appears widely in drug legislation without clear definition. Many assume only first-order derivatives—substances made in one reaction step—are covered, but this excludes substances like 2-carbomethoxytropinone, convertible to cocaine in multiple steps, which courts have ruled as controlled. The US Drug Enforcement Administration successfully argued in 1986 that buprenorphine, requiring six or more steps from thebaine, is a derivative. This ambiguity leaves the legal status of substances like 2-bromo-LSD uncertain. The authors suggest that unless qualified, the term should be avoided in future legislation.